What is CohBar, Inc. (CWBR) stock price today?

CohBar, Inc. (CWBR) is currently trading at $0.41, up 0% today.

What is CWBR P/E ratio?

CohBar, Inc.'s P/E ratio is -0.10. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CWBR return on equity (ROE)?

CohBar, Inc.'s return on equity (ROE) is -58.44%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CohBar, Inc.'s market cap?

CohBar, Inc. has a market capitalization of $1.19M.

NASDAQ · Biotechnology

CohBar, Inc. (CWBR) Stock

$0.41 +0.00% NASDAQ: CWBR Healthcare

CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs).

Valuation

Metric	Value
Price	$0.41
Market Cap	$1.19M
P/E Ratio	-0.10
P/B Ratio	0.08
P/S Ratio	0.00
EPS (TTM)	$-4.12
52-Week High	$1.01
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-58.44%
ROA	-73.09%
ROCE	-80.80%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	15.69

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-15.0M	$-13.0M	$-13.0M	$-15.0M	$-12.0M
Net Profit	$-16.0M	$-14.0M	$-15.0M	$-15.0M	$-12.0M
EPS	$-11.42	$-9.56	$-8.99	$-6.94	$-4.12
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$23.0M	$14.0M	$22.0M	$27.0M	$16.0M
Total Liabilities	$5.0M	$5.0M	$3.0M	$2.0M	$1.0M
Cash	$6.0M	$13.0M	$3.0M	$5.0M	$6.0M
Borrowings	$3.0M	$3.0M	$1.0M	$0	$0

Latest News

OP Pohjola's President and Group CEO Timo Ritakallio has announced that he will retire on 1 July 2027 as specified in his executive contract GlobeNewswire · Jul 23, 2026 Tocvan Discovers New High-Grade At-Surface Silver-Gold Zone 900 m East of Pilot Facility at Gran Pilar Project ACCESS Newswire · Jul 23, 2026 Constellation Brands Shareholders Approve Directors, Pay and Incentive Plan at Annual Meeting MarketBeat · Jul 23, 2026 Eco (Atlantic) Oil and Gas Ltd Announces Audited Results for the Year Ended 31 March 2026 ACCESS Newswire · Jul 23, 2026 OP Corporate Bank plc's Half-year Financial Report 1 January–30 June 2026 GlobeNewswire · Jul 23, 2026

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-10.0M	$-10.0M	$-10.0M	$-14.0M	$-10.0M
Investing Cash Flow	$-12.0M	$16.0M	$-18.0M	$-3.0M	$12.0M
Financing Cash Flow	$1.0M	$1.0M	$-1.0M	$2.0M	$0
Net Cash Flow	$3.0M	$7.0M	$-10.0M	$2.0M	$1.0M
Free Cash Flow	$-11.0M	$-10.0M	$-10.0M	$-14.0M	$-10.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.03
EV / EBITDA	0.39
FCF Yield	-876.50%
Quick Ratio	15.69
Interest Coverage	-1214.30
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BLCMBellicum Pharmaceuticals, Inc.	$0.07	-6.68%	-0.09	$778326	0.00%
CYTOAltamira Therapeutics Ltd.	$0.30	+100.00%	-0.02	$1.13M	0.00%
HTGMQHTG Molecular Diagnostics, Inc.	$0.00	—	0.00	$221	0.00%
IMPLImpel Pharmaceuticals Inc.	$0.04	-27.27%	-0.01	$956000	0.00%
NBSENeuBase Therapeutics, Inc.	$0.38	-1.56%	-0.02	$1.42M	0.00%

About CohBar, Inc.

CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.

CohBar, Inc. is headquartered in US.

CohBar, Inc. (CWBR) stock trades at $0.41 with a market capitalization of $1.19M. The stock is valued at a price-to-earnings (P/E) ratio of -0.10, price-to-book of 0.08, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $1.01, and currently trades 59.4% below its 52-week high.

On profitability, CohBar, Inc. generates a return on equity (ROE) of -58.44%, return on capital employed of -80.80%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cohbar.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides